Innovation in bone healing and tissue repair

Dr. Ivan Cohen-Tanugi - Chief Executive Officer

Dr. Ivan Cohen-Tanugi joins Kuros with more than 20 years of experience in leadership roles in the life sciences industry. He held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys. He received his medical degree at Grenoble School of Medicine, France, and obtained a MBA at H.E.C. Business School, Paris, France. Dr. Cohen-Tanugi is French and US citizen.

Didier Cowling - Founder and President

Didier Cowling co-founded Kuros in early 2002 and has been its CEO until April 2017. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Prof. Joost de Bruijn - Chief Executive Officer of Xpand Biotechnology

Joost de Bruijn founded Xpand Biotechnology BV in 2005 and was Chief Executive Officer of Xpand ever since. He continues in this role after the acquisition by Kuros in early 2017. Dr. de Bruijn also holds the positions of Professor of Biomaterials at Queen Mary University of London, UK (since 2004) and Professor of Regenerative Medicine and Entrepreneurship at Twente University, the Netherlands (since 2011). In 2007, he founded Progentix Orthobiology that signed an exclusive development agreement with NuVasive in 2009 for a novel family of calcium phosphate synthetic bone substitutes. Prior to founding Xpand he was Research Director Bone at IsoTis for seven years, during which he specialized in bone tissue engineering technologies that were brought to clinical application. Dr. de Bruijn has more than 20 years experience in academia and the life science industry. He has published 165 papers in peer-reviewed journals, and is the inventor of 24 patent families. Dr. de Bruijn is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He received his PhD from Leiden University in 1993.

Dr. Alistair Irvine - Chief Business Officer

Alistair Irvine joined Kuros as director of business development in 2006 after a career as a technical and commercial consultant to the biotechnology industry. Prior to his work, he was deputy director of R&D operations manager at Innovata plc, where he managed research programs in the fields of gene expression, cell culture, polymer science and oncology. In addition, he was involved in business development. Prior, Dr. Irvine was head of biology at ML Laboratories plc, as well as sub-divisional head research and group leader immunotherapy at Cobra Therapeutics Ltd. He also was senior scientist with Therexsys Ltd. Dr. Irvine has been working in the biotechnology/medtech industry for over 20 years. Dr. Irvine holds a PhD in molecular biology from the University of Sheffield, UK, and a BSc in biochemistry from the University of Edinburgh, UK. He is British citizen.

Dr. Virginia Jamieson - Chief Medical Officer

Virginia Jamieson was appointed Chief Medical Officer (CMO) in March 2016 responsible for overseeing the clinical development of the projects. She previously worked for Kuros Biosurgery AG from 2005 until 2012 as medical director and then as CMO leading the clinical and regulatory functions.  Dr. Jamieson has over 25 years of experience in the pharmaceutical industry covering all phases of development in a wide variety of therapeutic areas, following a career in anesthesia. She obtained a BSc in Medical Sciences and Medical Degree from Edinburgh University, Scotland, a post-graduate fellowship in anesthesia from the Royal College of Anaesthetists in London, UK, and a Diploma in pharmaceutical medicine from the Royal College of Physicians in London, UK. Dr. Jamieson is a British citizen.

Dr. Philippe Saudan - Chief Development Officer

Dr. Philippe Saudan was appointed Chief Development Officer (CDO) in August 2016. He has spent more than 17 years in the pharmaceutical industry and held different management roles in R&D. Dr. Saudan has considerable experience in R&D and international project management of multidisciplinary programs. In his last position, he served as Chief Scientific Officer of Cytos Biotechnology, where he worked at the interface between pre-clinical research, manufacturing and development of several clinical projects. Since February 2016, Dr. Saudan was working as Head of Integration of Kuros Biosciences. In this position, he was closely involved in the different development programs in tissue repair and regeneration. Dr. Saudan holds a PhD in biology from the University of Lausanne, Switzerland. Dr. Saudan is a Swiss and British citizen.

Dr. Jason Schense - Founder and Chief Technology Officer

Dr. Schense is working as Chief Technology Officer (CTO) responsible for the ongoing operational activities. Prior to joining Kuros, Jason was employed as a project leader at Straumann Biologics where he spent a year developing novel synthetic matrices for enhanced osseous healing associated with dental implants. From 2000 to 2002, Dr. Schense was employed as a project scientist at Kuros Therapeutics, where he was responsible for synthetic and fibrin-based materials for both bone and wound repair. He received his PhD in 1999 from the California Institute of Technology, Pasadena/CA, USA, working with Prof. Jeffrey Hubbell for the development of modified fibrin matrices for nerve regeneration. From this combined work, Dr. Schense has earned 19 publications, 10 conference presentations and is named as a co-inventor on all the patents in the field of delivery of growth factors from fibrin and modification of fibrin that the Company has licensed for tissue regeneration from the ETHZ and Caltech. He earned his BSc in Chemical Engineering from the Massachusetts Institute of Technology, Cambridge/MA, USA. Dr. Schense is a US and Italian citizen.

Frank-Jan van der Velden - Head of Business Affairs and Finance of Xpand Biotechnology

Frank-Jan van der Velden was a co-founder of Xpand Biotechnology BV and acted as executive board member since then. He co-founded several other Dutch companies in the field of regenerative medicine, i.e. CellCoTec, Progentix Orthobiology and Materiomics. Before he co-founded Xpand, Mr. van der Velden was partner at management consultants Krüger & Partners for 10 years. Prior to that, he acted as director of Quote Media Holding. Currently, Mr. van der Velden is a board member of RiverDiagnostics International, member of the executive board of Materiomics and chairman of the supervisory board of TIIN Techfund III BV, a venture capital fund for technology start-ups. Mr van der Velden is a graduate of Erasmus University Rotterdam School of Management.

Harry Welten - Chief Financial Officer

Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Executive Committee

Dr. Ivan Cohen-Tanugi
Chief Executive Officer

Dr. Ivan Cohen-Tanugi joins Kuros with more than 20 years of experience in leadership roles in the life sciences industry. He held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys. He received his medical degree at Grenoble School of Medicine, France, and obtained a MBA at H.E.C. Business School, Paris, France. Dr. Cohen-Tanugi is French and US citizen.

Didier Cowling
Founder and President

Didier Cowling co-founded Kuros in early 2002 and has been its CEO until April 2017. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Prof. Joost de Bruijn
Chief Executive Officer of Xpand Biotechnology

Joost de Bruijn founded Xpand Biotechnology BV in 2005 and was Chief Executive Officer of Xpand ever since. He continues in this role after the acquisition by Kuros in early 2017. Dr. de Bruijn also holds the positions of Professor of Biomaterials at Queen Mary University of London, UK (since 2004) and Professor of Regenerative Medicine and Entrepreneurship at Twente University, the Netherlands (since 2011). In 2007, he founded Progentix Orthobiology that signed an exclusive development agreement with NuVasive in 2009 for a novel family of calcium phosphate synthetic bone substitutes. Prior to founding Xpand he was Research Director Bone at IsoTis for seven years, during which he specialized in bone tissue engineering technologies that were brought to clinical application. Dr. de Bruijn has more than 20 years experience in academia and the life science industry. He has published 165 papers in peer-reviewed journals, and is the inventor of 24 patent families. Dr. de Bruijn is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He received his PhD from Leiden University in 1993.

Dr. Alistair Irvine
Chief Business Officer

Alistair Irvine joined Kuros as director of business development in 2006 after a career as a technical and commercial consultant to the biotechnology industry. Prior to his work, he was deputy director of R&D operations manager at Innovata plc, where he managed research programs in the fields of gene expression, cell culture, polymer science and oncology. In addition, he was involved in business development. Prior, Dr. Irvine was head of biology at ML Laboratories plc, as well as sub-divisional head research and group leader immunotherapy at Cobra Therapeutics Ltd. He also was senior scientist with Therexsys Ltd. Dr. Irvine has been working in the biotechnology/medtech industry for over 20 years. Dr. Irvine holds a PhD in molecular biology from the University of Sheffield, UK, and a BSc in biochemistry from the University of Edinburgh, UK. He is British citizen.

Dr. Virginia Jamieson
Chief Medical Officer

Virginia Jamieson was appointed Chief Medical Officer (CMO) in March 2016 responsible for overseeing the clinical development of the projects. She previously worked for Kuros Biosurgery AG from 2005 until 2012 as medical director and then as CMO leading the clinical and regulatory functions.  Dr. Jamieson has over 25 years of experience in the pharmaceutical industry covering all phases of development in a wide variety of therapeutic areas, following a career in anesthesia. She obtained a BSc in Medical Sciences and Medical Degree from Edinburgh University, Scotland, a post-graduate fellowship in anesthesia from the Royal College of Anaesthetists in London, UK, and a Diploma in pharmaceutical medicine from the Royal College of Physicians in London, UK. Dr. Jamieson is a British citizen.

Dr. Philippe Saudan
Chief Development Officer

Dr. Philippe Saudan was appointed Chief Development Officer (CDO) in August 2016. He has spent more than 17 years in the pharmaceutical industry and held different management roles in R&D. Dr. Saudan has considerable experience in R&D and international project management of multidisciplinary programs. In his last position, he served as Chief Scientific Officer of Cytos Biotechnology, where he worked at the interface between pre-clinical research, manufacturing and development of several clinical projects. Since February 2016, Dr. Saudan was working as Head of Integration of Kuros Biosciences. In this position, he was closely involved in the different development programs in tissue repair and regeneration. Dr. Saudan holds a PhD in biology from the University of Lausanne, Switzerland. Dr. Saudan is a Swiss and British citizen.

Dr. Jason Schense
Founder and Chief Technology Officer

Dr. Schense is working as Chief Technology Officer (CTO) responsible for the ongoing operational activities. Prior to joining Kuros, Jason was employed as a project leader at Straumann Biologics where he spent a year developing novel synthetic matrices for enhanced osseous healing associated with dental implants. From 2000 to 2002, Dr. Schense was employed as a project scientist at Kuros Therapeutics, where he was responsible for synthetic and fibrin-based materials for both bone and wound repair. He received his PhD in 1999 from the California Institute of Technology, Pasadena/CA, USA, working with Prof. Jeffrey Hubbell for the development of modified fibrin matrices for nerve regeneration. From this combined work, Dr. Schense has earned 19 publications, 10 conference presentations and is named as a co-inventor on all the patents in the field of delivery of growth factors from fibrin and modification of fibrin that the Company has licensed for tissue regeneration from the ETHZ and Caltech. He earned his BSc in Chemical Engineering from the Massachusetts Institute of Technology, Cambridge/MA, USA. Dr. Schense is a US and Italian citizen.

Frank-Jan van der Velden
Head of Business Affairs and Finance of Xpand Biotechnology

Frank-Jan van der Velden was a co-founder of Xpand Biotechnology BV and acted as executive board member since then. He co-founded several other Dutch companies in the field of regenerative medicine, i.e. CellCoTec, Progentix Orthobiology and Materiomics. Before he co-founded Xpand, Mr. van der Velden was partner at management consultants Krüger & Partners for 10 years. Prior to that, he acted as director of Quote Media Holding. Currently, Mr. van der Velden is a board member of RiverDiagnostics International, member of the executive board of Materiomics and chairman of the supervisory board of TIIN Techfund III BV, a venture capital fund for technology start-ups. Mr van der Velden is a graduate of Erasmus University Rotterdam School of Management.

Harry Welten
Chief Financial Officer

Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.